Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 12, Pages 4306-4313Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI60658
Keywords
-
Categories
Funding
- NHLBI NIH HHS [P01 HL108797, R01 HL074186] Funding Source: Medline
Ask authors/readers for more resources
Recent clinical and experimental studies are redefining the cellular and molecular bases of pulmonary, arterial hypertension (PAH). The genetic abnormalities first identified in association with the idiopathic form of PAH - together with a vast increase in our understanding of cell signaling, cell-transformation, and cell-cell interactions; gene expression; microRNA-processing; and mitochondrial and ion channel function - have helped explain the abnormal response of vascular cells to injury. Experimental and clinical studies now. converge on the intersection and interactions between a genetic predisposition involving the BMPR2 signaling Pathway and an unpaired metabolic and chronic inflammatory state hi the vessel wall The deranged processes' culminate in an exuberant proliferative response that occludes the pulmonary arterial (PA) lumen and obliterates the most distal intraacinar vessels. Here, we describe emerging therapies based on preclinical studies that address these converging pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available